Clinical Trial Update: Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin [Phase 1]

View source ↗

Summary

Phase 1 ascending multi-dose trial of REGN727 (alirocumab) with and without atorvastatin for hypercholesterolemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• REGN727 (SAR236553) (alirocumab)
• atorvastatin (atorvastatin)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED